-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The data comes from the experiment of the experimental dipeptidyl peptidase (DPP) inhibitor BXCL701 developed by BioXcel Therapeutics and was published in the "Journal of Cancer Immunotherapy" on November 4, 2021
"This combination therapy not only cured some mice, but also showed that immune cell memory
The National Cancer Institute estimates that there will be 60,430 newly diagnosed cases of pancreatic cancer in 2021, and an estimated 48,220 deaths
The microenvironment surrounding most pancreatic tumors is very effective in blocking immune system attacks, so the researchers turned to BXCL701, an experimental oral DPP inhibitor
The corresponding author of the study, Louis M.
The scientists studied two groups of mice, which were injected with cells similar to human pancreatic cancer
Natural killer cells play a key role in the immune defense against cancer in two ways: They recognize and directly kill cancer cells, similar to T cells, but also release small signaling molecules that can affect and regulate other parts of the immune system.
Fitzgerald said: "We want to do more research on mice to better understand the biological principles of why this treatment is so effective, and how we can make it work better
Journal Reference :
Allison A Fitzgerald, Shangzi Wang, Veena Agarwal, Emily F Marcisak, Annie Zuo, Sandra A Jablonski, Melanie Loth, Elana J Fertig, John MacDougall, Eugene Zhukovsky, Shubhendu Trivedi, Dimple Bhatia, Vince O'Neill, Louis M Weiner.
